Schema-Root.org logo

 

  cross-referenced news and research resources about

 Novartis

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Fri. April 27, 2018

-
Novartis sued a former executive last summer after she left the Swiss drugmaker to join Cambridge-based Biogen as head of U.S. sales and marketing, accusing her of using a USB drive to steal trade secrets on her way out the door. The lawsuit, which has not been previously reported, stems from ...
Karande left Novartis to take a vice president role at Intarcia, where he was also the general manager for the company's ITCA 650 product, a temperature-stable form of exenatide delivered by a matchstick-sized pump implanted just beneath the skin. He left Intarcia in March, just a month after the ...
This week saw the headline-grabbing multi-billion dollar sell-off by Novartis of its consumer healthcare business. Reflecting the Swiss entity's desire to focus resources on strengthening its position in higher-priority therapeutic spaces, the deal provides funds that are likely to be used for acquisitions ... pharma
The intellectual property in question, known as patent '688, covers a vector for expression of a polypeptide in a mammalian cell, and was ultimately used in the development of Novartis' Lucentis. The Swiss pharma contends that to produce Eylea and Zaltrap, Regeneron tapped a commercial ...

Novartis Pharma, the Switzerland-based pharmaceuticals manufacturer is strengthening its focus on digitalisation and data. With the company's focus in these two areas already making an impact in the last 2-3 years, Hyderabad operations are all set to contribute to its global operations in data analytics ...
Now the Boston/Bay Area-based biotech will work with Joris van Dam, the executive director for digital therapeutics at the Novartis Institutes for BioMedical Research, on interactive digital programs for schizophrenia and multiple sclerosis. Getting a heavyweight player in the biopharma industry to ...
It's far from the first time Novartis has tapped tech partners to further its goals for prescription drugs. Among its deals is a team-up with Qualcomm aimed at using the wireless giant's connected devices and in-home collection stations to monitor patients in clinical studies, and they're developing a smart ...
early a dozen advocacy groups began a series of protests against Novartis this week for using “lies, threats and bribes” to pressure developing countries not to pursue measures to widen access to medicines. The groups are targeting Novartis because the drug maker figures prominently in an intensifying ...
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It's the first time a pharma company has made a development deal with a digital therapeutic, according to Pear. “We have been in ...
Spencer Fisk jumped to Rubius just a few days ago, joining what seems to be a steady migration out of Novartis' cell and gene therapy operation. He was the global head of Cell and Gene Technical Development and Manufacturing. Fisk took the place of Karen Walker, who left for Seattle Genetics last ...
Stimunity, a Parisian biotech, secured a 2M€ seed investment to develop a cancer treatment that could compete with that of big players such as Merck and Novartis. Stimunity is a preclinical-stage startup company which develops drugs targeting a new cell signalling pathway to treat cancer. The company ...
China upstart EpimAb Biotherapeutics has wooed in a top researcher from Novartis as its first chief medical officer. Bin Peng, who had been global chief of oncology translational medicine at NIBR's Shanghai group, is jumping to the startup, which grabbed a $25 million launch round last April and is allied ...
In an unexpected twist to the bribery probe Novartis faces in Greece, the Swiss pharma's Athens headquarters was vandalized by anarchists. About 30 people launched the assault at around 5 a.m. Sunday local time, smashed windows and splashed red paint at the building, according to local police report ...
Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per milliliter injection of the ...
Swiss pharmaceuticals company Novartis will move toward making a decision on the fate of Alcon -- its eye care business -- in the first half of 2019, its chief executive officer reiterated on Sunday. "With Alcon ... we look forward to taking a potential action, moving toward a potential decision in the first half ...
The logo of Swiss drugmaker Novartis is seen outside the company's offices in Athens, Greece, February 6, 2018. ... ATHENS (Reuters) - Greek self-proclaimed anarchists threw paint and smashed windows at the entrance of the Athens headquarters of Swiss drugmaker Novartis on Sunday, police said. CEO
The head of the Greek prime minister's legal department, Vassiliki Thanou, has come under fire from the country's union of judges and prosecutors (EDE), who described her recent intervention in the Novartis bribery case as an “institutional faux pas.” In comments made earlier this week, Thanou, a former ... CEO
So Novartis is looking to new heart data to give contender Ultibro Breezhaler an edge. Data published in Lancet Respiratory Medicine show Ultibro beat out placebo at significantly improving both cardiac and lung function in COPD patients with lung hyperinflation. The study, known as Claim, is the first to ... CEO
Cosentyx has the potential to become a blockbuster drug in each of its approved indications. CAR-T therapy, Kymriah, is testimony to the superior scientific capability of Novartis. Novartis also has a robust oncology portfolio targeting multiple indications. Novartis, however, continues to face multiple ... CEO
The governor of the Bank of Greece, Yannis Stournaras; Europe's migration commissioner, Dimitris Avramopoulos and the country's former prime minister Antonis Samaras are among those accused of giving Novartis preferential market treatment. “We will not cover up,” Samaras's successor, Alexis Tsipras, ... CEO
A fierce battle is expected to take place in the Greek parliament on Wednesday as political leaders speak and vote on the formation of a special committee on the Novartis case. Indicative of the intentions of the 10 political figures allegedly involved in the Novartis scandal is a statement made by PASOK ... CEO
Novartis AG NVS ended 2017 on a positive note, courtesy of strong performance of psoriasis drug, Cosentyx. Cosentyx achieved multi-blockbuster drug status in 2017 on the back of strong growth in three approved indications - psoriasis, ankylosing spondylitis and psoriatic arthritis. The drug has grabbed ... CEO
Less than one week after it scored approval from the FDA for Glatopa (glatiramer acetate injection), a generic version of Teva's multiple sclerosis drug Copaxone, Novartis may be looking to sell off its generics subsidiary Sandoz, BioSpace reports. Citing unnamed sources “familiar with the matter,” Reuters ... CEO
Novartis shows duration of effect and improved quality of life in patients with psoriasis using Cosentyx over a 5-year period. Novartis' Cosentyx was shown to be superior to J&J Stelara, but Tremfya is not that far behind. Cosentyx has also been approved by the FDA for other psoriasis indications. Sales of ... CEO
In 2016, Novartis undertook a major shake-up of its research and development operations, bringing in Vas Narasimhan to a newly-created role of chief medical officer, and appointing Harvard University haemato-oncologist Jay Bradner as the new head of the Novartis Institutes for BioMedical Research ... CEO
Anti-corruption prosecutors and police have been searching homes and workplaces linked to the Novartis case over the last few days, Kathimerini has ... by anti-corruption prosecutor Eleni Touloupaki, who is leading the investigation into claims that pharmaceutical giant Novartis bribed Greek politicians. CEO
All we have is the top-line result against a placebo, though, in a field where Novartis $NVS has continued to expand on longterm outcomes for patients with its first-to-market blockbuster Cosentyx. Lilly boasts that Taltz scored on the primary and all the secondaries in the study as it preps new regulatory ... CEO
Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per milliliter injection of the ... CEO
As Novartis battles Regeneron for a piece of its blockbuster Eylea franchise, Roche/Genentech $RHHBY is coming up quietly with a next-gen bispecific antibody which posted encouraging Phase II results late Sunday. RG7716 is a dual anti-VEGF/anti-angiopoietin-2 antibody that targets retinal eye ... CEO
Pharmaceutical giant Novartis AG has come under investigation in Greece on allegations that the Swiss group bribed officials and doctors to fix drug prices and boost its sales to public hospitals. Greek prosecutors sent a report to the parliament alleging that Novartis bribed officials and doctors earlier this ... CEO
For 4Q17, Novartis (NVS) reported revenues of ~$12.9 billion, which represents a YoY (year-over-year) rise of 5% on a reported basis and a rise of 2% on a CC (constant currency) basis. Although the rising sales volumes of the recently launched Entresto and Cosentyx contributed around 7 percentage points to the ... CEO
The government has decided to opt for the formation of a parliamentary committee to probe claims by prosecutors that Greek politicians took bribes from the Swiss drugs manufacturer Novartis even amid protests by some over the reliability of the testimonies on which the case has been built. Prime Minister ... CEO
A letter to the department indicates Novartis' intent to terminate those 65 employees over a two-week period. About 450 employees will be laid off when the Broomfield facility shuts down. Those layoffs "will occur in approximately three waves ending is 2019," the letter, dated Feb. 6, said. The company is ... CEO
There's been no shortage of ink spilled by analysts, market watchers, patient advocates and others to dissect CAR-T pricing. Now, a new analysis suggests Novartis could make a decent profit on Kymriah if the cost was just one-third its current price, but the drugmaker disagrees with some of the paper's key ... CEO
Prime Minister Alexis Tsipras will be recommending the formation of a parliamentary committee to conduct a preliminary inquiry into claims made in a prosecutors' report that several high-ranking politicians were bribed by Swiss drugs firm Novartis. “The committee's only task will be to explore the charges ... CEO
Novartis is in the middle of a corruption scandal in Greece. The company is accused of bribing ten former government officials with a sum worth several millions of euros. Centogene has reached a big milestone: the German company has identified one billion gene variants that contribute to rare diseases. CEO
Just days after 10 former ministers in Greece were implicated in bribery allegations against Novartis, the country's prime minister is calling for a special parliamentary committee to investigate the charges, which have been pegged as slanderous by some politicians pulled into the widening scandal. CEO
The FDA has now refused to approve the copycat, Novartis said Thursday. In a complete response letter, the agency asked for more data on the drug, which aimed to be a substitutable version of GlaxoSmithKline's big-selling respiratory drug Advair. The Swiss drugmaker now says it's “highly unlikely” the ... CEO
Avramopoulos, whose name is mentioned in the Novartis case involving Swiss pharmaceutical giant Novartis and 10 Greek politicians. “I learned today about the contents of the unsubstantiated case, which is riddled with holes. It is now obvious that it is an unprecedented conspiracy that could not be ... CEO
The market cap of 228.97B for Novartis AG in today's market indicated its current strength, making the company's shares a lucrative one. The company's existing price is $86.23 with a change in volume of 3,530,432. Novartis AG's target price was set to $97.06 with an IPO date at . The Return on Equity ... CEO
Greek prosecutors have named eight former ministers and two former prime ministers in connection with a major corruption investigation. Investigators allege the pharmaceutical company Novartis paid doctors to prescribe its drugs at high prices. Prosecutors said the former politicians received bribes, but ... CEO
Based on the aggregate value of the company over its current share price and the total amount of outstanding stocks, the market cap of Novartis AG (NVS) is presently reeling at 225.25B. Acting as the blue chip in today's trade, Novartis AG's existing market cap value showcases its prevailing assets, capital ... CEO
Greece's justice minister Stavros Kontonis said at the time that Novartis had likely bribed "thousands" of doctors and civil servants to promote its products and continued to sell "overpriced" drugs even after the country was hit by economic crisis in 2010 and huge cuts were imposed on state budgets, leaving ... CEO
One year after officials in Greece began investigating Novartis on allegations that the company bribed both doctors and government figures to boost its sales, the country's leaders are ratcheting up the probe—implicating 10 former ministers in the scandal and ordering one of the Swiss pharma giant's local ... CEO
The Supreme Court's Public Prosecution Office is to submit to Parliament a case file concerning an ongoing probe into charges that Swiss drug firm Novartis paid bribes in order to receive preferential treatment, so that lawmakers can decide whether eight former ministers and two ex-premiers should be ... CEO


 

news and opinion


 


 


 


 


schema-root.org

     novartis

pharmaceutical industry:
     allergan
     ariad
     astrazeneca
     baxter
     eli lilly
     glaxosmithkline
     merck
     mylan
     novartis
     pfizer
     products
     purdue pharma
     research
     takeda
     teva
     upjohn
     valeant